Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Central Africa has been witnessing a steady growth in recent years.
Customer preferences: The increasing prevalence of cancer in the region has led to a growing demand for oncology drugs. Patients in Central Africa are increasingly seeking access to affordable and effective treatments to combat cancer. This has resulted in a shift towards targeted therapies and immunotherapies, which offer better outcomes with fewer side effects.
Trends in the market: The oncology drugs market in Central Africa is witnessing several trends. Firstly, there is a growing trend towards the use of biosimilars, which are more affordable versions of expensive biologic drugs. Secondly, there is a shift towards the use of combination therapies, which involve the use of two or more drugs to treat cancer. This approach has been shown to be more effective than using a single drug. Finally, there is a trend towards the use of personalized medicine, which involves tailoring treatments to individual patients based on their genetic makeup.
Local special circumstances: Central Africa faces several challenges in the oncology drugs market. Firstly, there is a lack of access to healthcare in many parts of the region, which limits the availability of oncology drugs. Secondly, there is a lack of infrastructure and trained personnel to administer oncology drugs. Finally, there is a lack of awareness about cancer and its treatment, which leads to delays in diagnosis and treatment.
Underlying macroeconomic factors: The growth of the oncology drugs market in Central Africa is driven by several macroeconomic factors. Firstly, there is a growing middle class in the region, which has led to an increase in healthcare spending. Secondly, there is a growing burden of cancer in the region, which has led to an increase in demand for oncology drugs. Finally, there is a growing trend towards universal healthcare coverage, which has led to an increase in access to oncology drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
